Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

Abstract

The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.

1 . Use of one or more of the compounds of formula (I)  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  hydrogen, halogen, cyano, trifluoromethyl, hydroxy, benzyloxy, aminocarbonyl, carboxy, phenyl, phenoxy, phenylthio, pyridyloxy, pyridylthio, alkyl, especially C 1 -C 6 -alkyl, 
 alkenyl, especially C 3 -C 6 -alkenyl,  
 alkinyl, especially C 3 -C 6 -alkinyl,  
 hydroxyalkyl, especially C 1 -C 6 -hydroxyalkyl,  
 alkoxy, especially C 1 -C 6 -alkoxy,  
 alkenyloxy, especially C 3 -C 6 -alkenyloxy,  
 alkinyloxy, especially C 3 -C 6 -alkinyloxy,  
 alkanoyloxy, especially C 1 -C 7 -alkanoyloxy,  
 alkoxycarbonyloxy, especially C 2 -C 7 -alkoxycarbonyloxy,  
 alkylthio, especially C 1 -C 6 -alkylthio,  
 alkenylthio, especially C 3 -C 6 -alkenylthio,  
 alkinylthio, especially C 3 -C 6 -alkinylthio,  
 cycloalkyl, especially C 3 -C 8 -cycloalkyl,  
 cycloalkyloxy, especially C 3 -C 8 -cycloalkyloxy,  
 cycloalkylthio, especially C 3 -C 8 -cycloalkylthio,  
 alkoxycarbonyl, especially C 2 -C 7 -alkoxycarbonyl,  
 alkylaminocarbonyl, especially C 2 -C 7 -alkylaminocarbonyl,  
 dialkylaminocarbonyl, especially C 3 -C 13 -dialkylaminocarbonyl, or  
 NRSR 6 , wherein 
 R 5  and  
 R 6  are selected independently of each other from hydrogen, 
 alkyl, especially C 1 -C 6 -alkyl,  
 alkenyl, especially C 3 -C 6 -alkenyl and  
 alkinyl, especially C 3 -C 6 -alkinyl,  
 
 
 
 R 2  is hydrogen, halogen, cyano, hydroxy, trifluoromethyl, benzyloxy, 
 alkyl, especially C 1 -C 6 -alkyl,  
 alkoxy, especially C 1 -C 6 -alkoxy or  
 alkanoyloxy, especially C 1 -C 7 -alkanoyloxy,  
 wherein R 1  and R 2 , if they are adjacent, optionally form a bridge which is selected from  
 —(CH 2 ) 4 —, —(CH═C) 2 — and —CH 2 O—CR 7 R 8 —O—, wherein 
 R 7  and  
 R 8  are, independently of each other, hydrogen or alkyl, especially C 1 -C 6 -alkyl,  
 
 
 R 3  is hydrogen, halogen, alkyl, especially C 1 -C 6 -alkyl, trifluoromethyl or hydroxyalkyl, especially C 1 -C 6 -hdroxyalkyl and  
 R 4  is hydrogen, hydroxy, benzyloxy, 
 alkyl, especially C 1 -C 6 -alkyl,  
 alkenyl, especially C 3 -C 6 -alkenyl,  
 alkinyl, especially C 3 -C 6 -alkinyl,  
 cycloalkyl, especially C 3 -C 6 -cycloalkyl or  
 alkoxy, especially C 1 -C 6 -alkoxy,  
 
 k is 0 or 1,  
 A is alkylene, especially C 1 -C 6 -alkylene, which is optionally substituted once to three-fold by alkyl, especially C 1 -C 3 -alkyl, hydroxy, alkoxy, especially C 1 -C 3 -alkoxy, fluorine or phenyl, or 
 1,2-cyclopropylene or  
 alkenylene with at least than two C-atoms, especially C 2 -C 6 -alkenylene, which is optionally substituted once to three-fold by C 1 -C 3 -alkyl, hydroxy, C 1 -C 3 -alkoxy, fluorine, cyano or phenyl,  
 alkadienylene with at least four C-atoms, especially C 4 -C 6 -alkadienylene, which is optionally substituted once or twice by C 1 -C 3 -alkyl, fluorine, cyano or phenyl,  
 1,3,5-hexatrienylene, which is optionally substutited by C 1 -C 3 -alkyl, fluorine, cyano, or phenyl,  
 ethinylene or  
 alkylene with at least two C-atoms, especially C 2 -C 6 -alkylene in which a methylene unit can be isosterically replaced by O, S, NR 9 , CO, SO or SO 2 , wherein the substitution, with the exception of ═CO, cannot be adjacent to the amide group and wherein 
 R 9  is selected from hydrogen, alkyl, especially C 1 -C 6 -alkyl, alkenyl, especially C 3 -C 6 -alkenyl, alkinyl, especially C 3 -C 6 -alkinyl, acyl, especially C 1 -C 6 -acyl or alkylsulfonyl, especially C 1 -C 6 -alkylsulfonyl,  
 
 
 D is selected from alkylene, especially C 1 -C I-alkylene, optionally substituted once or twice by alkyl, especially C 1 -C 6 -alkyl, hydroxy, or alkoxy, especially C 1 -C 6 -alkoxy,  
 alkenylene with at least two C-atoms, especially C 2 -C 10 -alkenylene, which is optionally substituted once or twice by alkyl, especially C 1 -C 6 -alkyl, hydroxy, or alkoxy, especially C 1 -C 6 -alkoxy, wherein the double bond can also be to ring E,  
 alkinylene with at least three C-atoms, especially C 3 -C 10 -alkinylene, optionally substituted once or twice by alkyl, especially C 1 -C 6 -alkyl, hydroxy or alkoxy, especially C 1 -C 6 -alkoxy, and  
 alkylene, especially C 1 -C 10 -alkylene, alkenylene with at least two C-atoms, especially C 2 -C 1 -alkenylene or alkinylene with at least three C-atoms, especially C 3 -C 1 -alkinylene, whereby one to three methylene units are each isosterically replaced by O, S, NR 10 , CO, SO or SO 2  wherein 
 R 10  has the same meaning as  
 
 R 9  but is selected independently thereof,  
 E is selected from  
                     
  wherein the heterocyclic ring can also optionally have a double bond and  
 n and  
 p can be, independently of one another 0, 1, 2 or 3, with the proviso that n+p≦4 and  
 q is 2 or 3,  
 R 11  is hydrogen, alkyl, especially C 1 -C 6 -alkyl, hydroxy, hydroxymethyl, carboxy or alkoxycarbonyl with at least two C-atoms, especially C 2 -C 7 -alkoxycarbonyl and  
 R 12  is hydrogen, alkyl, especially C 1 -C 6 -alkyl or or an oxo group adjacent to the nitrogen atom, wherein  
 R 11  and R 12  optionally together, form an alkylene bridge with 1, 2, 3, 4 or 5 C-atoms, especially a C 1 -C 3 -alkylene bridge under formation of a bicyclic ring system,  
 G is selected from hydrogen, 
 G1, G2, G3, G4 and GS, wherein 
 G1 represents the residue  
 —(CH 2 ) r —(CR 14 R 16 ) s —R 13   (G1)  
  wherein 
 r is an integer from 1 to 3 or 0 and  
 s is 0 or 1,  
 
 
 
 R 13  is selected from hydrogen, alkyl, especially C 1 -C 6 -alkyl, alkenyl with at least three C-atoms, especially C 3 -C 6 -alkenyl, alkinyl with at least three C-atoms, especially C 3 -C 6 -alkinyl, cycloalkyl with at least three C-atoms, especially C 3 -C 8 -cycloalkyl, 
 saturated, five to seven membered heterocycles, which can contain one or two hetero-atoms from the group N and/or S and/or O,  
 benzyl or phenyl,  
 monocyclic aromatic five or six-membered heterocycles, which can contain one to three hetero-atoms from the group N and/or S and/or O and are either bound directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated carbocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein the linkage can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms can be selected from N and/or S and/or O and the linkage can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 
 R 14  has the same meaning as R 13 , but is selected independently thereof,  
 R 15  is selected from hydrogen, hydroxy, methyl, benzyl, phenyl, 
 monocyclic aromatic five- or six-membered heterocycles, which can contain one to three hetero-atoms selected from the group N and/or S and/or O and are either bound directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated carbocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein the linkage can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms can be selected from N and/or S and/or O and the linkage can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 
 G2 is the residue  
                     
  wherein the substituents R 13  and R 15  can have the above meaning or the grouping  
 NR 13 R 15    
  can also be a nitrogen heterocycle bound over the nitrogen atom, selected from 
 saturated or unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from the essential nitrogen atom, can optionally contain one or two further hetero-atoms selected from the group N and/or S and/or O, or  
 saturated or unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from the essential nitrogen atom, can optionally contain one or two further hetero-atoms selected from the group N and/or S and/or O,  
 
 G3 is the residue  
 —SO 2  (CH 2 ) r  R 13   (G3)  
  and  
 G4 is the residue  
                     
  wherein 
 Ar 1  and Ar 2  are selected independendy from one another from phenyl, pyridyl or naphthyl and  
 
 G 5  is the residue  
 —COR 16   (G5)  
  wherein  
 R 16  is selected from trifluoromethyl, alkoxy, especially C 1 -C 6 -alkoxy, alkenyloxy, especially C 3 -C 6 -alkenyloxy, or benzyloxy,  
 wherein any aryl residues and/or aromatic ring systems in the substituents R 1 , R 2 , R 4 , R 13 , R 14 , R 15 , R 16 , Ar 1  and Ar 2  and/or in the ring system —NR 13 R 15  can be substituted independently from each other by one to three of the same or different residues which are selected from halogen, cyano, alkyl, especially C 1 -C 6 -alkyl, trifluoromethyl, cycloalkyl, especially C 3 -Cg-cycloalkyl, phenyl, benzyl, hydroxy, alkoxy, especially C 1 -C 6 -alkoxy, alkoxy, substituted entirely or partially by fluorine, substituted alkoxy, especially C 1 -C 6 -alkoxy, benzyloxy, phenoxy, mercapto, alkylthio, especially C 1 -C 6 -alkylthio, carboxy, alkoxycarbonyl, especially C 1 -C 6 -alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, monoalkylamino, especially mono-C 1 -C 6 -alkylamino, dialkylamino, especially di-(C 1 -C 6 -alkyl)-amino and methylenedioxy for two adjacent groups on the aromatic ring or ring system,  
 wherein each of the residues alkyl, alkenyl, alkinyl, hydroxyalkyl, alkoxy, alkenyloxy, alkinyloxy, alkanoyloxy, alkoxycarbonyl, alkoxycarbonyloxy, alkylthio, alkenylthio, alkinylthio, alkylene, acyl, alkylsulfonyl, alkenylene, alkinylene, cycloalkyl, cycloalkyloxy, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl of the substituents R 1  to R 14  can have 1 to 2 or 4, 6, 8, 10 or 12 C-atoms and/or 2 or 3 to 5, 7, 9, 11 or 13 and/or 15 C-atoms or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 C-atoms depending on the structure, as well as  
 stereoisomers and/or mixtures thereof and pharmacologically acceptable acid addition salts thereof  
 for the production of medicaments for cytostatic or immunomodulatory and/or immunosuppressive treatment.  
 
     
     
         2 . Use according to  claim 1 , characterized in that compounds used in the production of medicaments are contained in formula (I)  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  is a hydrogen, halogen, cyano, C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl, C 3 -C 6 -alkinyl, trifluoromethyl, C 3 -C 8  cycloalkyl, C 1 -C 6 -hydroxyalkyl, hydroxy, C 1 -C 6 -alkoxy, C 3 -C 6 -alkenyloxy, C 3 -C 6 -alkinyloxy, benzyloxy, C 1 -C 7 -alkanoyloxy, C 2 -C 7 -alkoxycarbonyloxy, C 1 -C 6 -alkylthio, C 3 -C 6 -alkenylthio, C 3 -C 6 -alkinylthio, C 3 -C 8 -cycloalkyloxy, C 3 -C 8 -cycloalkylthio, C 2 -C 7 -alkoxycarbonyl, aminocarbonyl, C 2 -C 7 -alkylaminocarbonyl, C 3 -C 13 -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, phenylthio, pyridyloxy, pyridylthio, or NR 5 R 6 , wherein 
 R 5  and  
 R 6  are selected independently from each other from hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl and C 3 -C 6 -alkinyl,  
 
 R 2  is hydrogen, halogen, cyano, C 1 -C 6 -alkyl, trifluoromethyl, hydroxy, C 1 -C 6 -alkoxy, benzyloxy or C 1 -C 7 -alkanoyloxy, 
 wherein R 1  and R 2 , in case they are adjacent, optionally form a bridge which is selected from the bridge members  
 —(CH 2 ) 4 — and —(CH═CH) 2 — and —CH 2 O—CR 7 R 8 —O—, wherein 
 R 7  and  
 R 8  are, independently from each other, hydrogen or C 1 -C 6 -alkyl,  
 
 
 R 3  is hydrogen, halogen, C 1 -C 6 -alkyl, trifluoromethyl or C 1 -C 6 -hydroxyalkyl and  
 R 4  is hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl, C 3 -C 6 -alkinyl, C 3 -C 6 -cycloalkyl, hydroxy, C 1 -C 6 -alkoxy or benzyloxy,  
 k is 0 or 1,  
 A is C 1 -C 6 -alkylene, which is optionally substituted once to three-fold by C 1 -C 3 -alkyl, hydroxy, C 1 -C 3 -alkoxy, fluorine or phenyl, or 
 1,2-cyclopropylene or  
 C 2 -C 6 -alkenylene, which is optionally substituted once to three-fold by C 1 -C 3 -alkyl, hydroxy, C 1 -C 3 -alkoxy, fluorine, cyano or phenyl,  
 C 4 -C 6 -alkadienylene, which is optionally substituted once or twice by C 1 -C 3 -alkyl, fluorine, cyano or phenyl  
 1,3,5-hexatrienylene, which is optionally substituted by C 1 -C 3 -alkyl, fluorine, cyano or phenyl  
 ethynylene or  
 C 2 -C 6 -alkylene, wherein a methylene unit can be isosterically replaced by O, S, NR 9 , CO, SO or SO 2 , wherein the isosteric substitution, with the exception of CO, cannot be adjacent to the amide group, and 
 R 9  is selected from hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl, C 3 -C 6 -alkinyl, C 1 -C 6 -acyl or C 1 -C 6 -alkylsulfonyl,  
 
 
 D is selected from C 1 -C 6 -alkylene, optionally substituted once or twice by C 1 -C 6 -alkyl, hydroxy, or C 1 -C 6 -alkoxy, 
 C 2 -C 10 -alkenylene, which is optionally substituted once or twice by C 1 -C 6 -alkyl, hydroxy, or C 1 -C 6 -alkoxy, wherein the double bond can also be to ring E,  
 C 3 -C 1 -alkinylene, optionally substituted once or twice by C 1 -C 6 -alkyl, hydroxy, or C 1 -C 6 -alkoxy, and  
 C 1 -C 10 -alkylene, C 2 -C 10 -alkenylene or C 3 -C 10 -alkinylene, wherein one to three methylene units are each isosterically replaced by O, S, NR 10 , CO, SO or SO 2 , wherein 
 R 10  has the same meaning as R 9 , but is selected independently therefrom,  
 
 
 E is selected from  
                     
  wherein the heterocyclic ring can optionally have a double bond and  
 n and  
 p can be, independently of each other, 0, 1, 2 or 3, with the proviso that n+p≦4 and  
 q is 2 or 3,  
 R 11  is hydrogen, C 1 -C 6 -alkyl, hydroxy, hydroxymethyl, carboxy or C 2 -C 7 -alkoxycarbonyl and  
 R 12  hydrogen, C 1 -C 6 -alkyl or an oxo group adjacent to the nitrogen atom, wherein  
 R 11  and R 12  optionally together form a C 1 -C 3 -alkylene bridge under formation of a bi-cyclic ring system,  
 G is selected from hydrogen, 
 G1, G2, G3, G4 and G5, wherein 
 G1 represents the residue  
 —(CH 2 ) r —(CR 14 R 15 ) s —R 13   (G1)  
  wherein 
 r is an integer from 1 to 3 or 0 and  
 s is 0 or 1,  
 
 
 
 R 13  is selected from hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl, C 3 -C 6 -alkinyl, C 3 -C 8 -cycloalkyl, 
 saturated, five- to seven-membered heterocycles, which can contain one or two hetero-atoms from the group N and/or S and/or O,  
 benzyl or phenyl,  
 monocyclic aromatic five or six-membered heterocycles, which can contain one to three hetero-atoms from the group N and/or S and/or O and are either bound directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated carbocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein the linkage can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms can be selected from N and/or S and/or O and the linkage can occur either over an aromatic, ring or a hydrated ring and either directly or over a methylene group,  
 
 R 14  has the same meaning as R 13 , but is selected independently thereof,  
 R 15  is selected from hydrogen, hydroxy, methyl, benzyl, phenyl, 
 monocyclic aromatic five- or six-membered heterocycles, which can contain one to three hetero-atoms selected from the group N and/or S and/or O and are either bound directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated carbocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein the linkage can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms can be selected from N and/or S and/or O and the linkage can occur either over an aromatic ring or a hydrated ring and either directly or over a methylene group,  
 
 G2 is the residue  
                     
  wherein the substituents R 13  and R 15  can have the above meaning or the grouping  
 —NR 13 R 15    can also he a nitrogen heterocycle bound over the nitrogen atom, selected from    saturated or unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from the essential nitrogen atom, can optionally contain one or two further hetero-atoms selected from the group N and/or S and/or O, or    saturated or unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from the essential nitrogen atom, can optionally contain one or two tirther hetero-atoms selected from the group N and/or S and/or O,    
 G3 is the residue  
 —SO 2 —(CH 2 ) r  R 13   (G3)  
  and  
 G4 is the residue  
                     
  wherein 
 Ar 1  and Ar 2  are selected independently from one another from phenyl, pyridyl or naphthyl and  
 
 G5 is the residue  
 COR 16   (G5)  
  wherein  
 R 16  is selected from trifluoromethyl, C 1 -C 6 -alkoxy, C 3 -C 6 -alkenyloxy, or benzyloxy, and wherein 
 aromatic ring systems in the substituents R 1 , R 2 , R 4 , R 13 , R 14 , R 15 , R 16  Ar 1  and Ar 2  and/or in the ring system —NR 13 R 15  can be substituted independently from each other by one to three of the same or different residues which are selected from halogen, cyano, C 1 -C 6 -alkyl, trifluoromethyl, C 3 -C 8 -Cycloalkyl, phenyl, benzyl, hydroxy, C 1 -C 6 -alkoxy, which can optionally be entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C 1 -C 6 -alkylthio, carboxy, C 1 -C 6 -alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C 1 -C 6 -alkylamino or di-(C 1 -C 6 -alkyl)-amino and methylenedioxy for two adjacent groups on the aromatic ring or ring system, their stereoisomers thereof and/or their mixtures thereof and pharmacologically acceptable acid addition salts.  
 
 
     
     
         3 . Use of the compounds according to  claim 1  or  2 , characterized in that the substituents R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 13 , R 14 , R 15  and R 16  as well as A and D indicated for formula (I) have the following meaning in connection with the given substitutions according to this formula  
       
         
           
           
               
               
           
         
       
       wherein 
 halogen is fluorine, chlorine, bromine or iodine,  
 C 1 -C 6 -alkyl can be straight chain or branched and is preferably a methyl-, ethyl-, propyl-, isopropyl-, butyl-, isobutyl-, sec-butyl-, tert-butyl-, cyclopropylmethyl-, pentyl-, isopentyl-, tert-pentyl-, neopentyl-, cyclopropylethyl-, cyclobutylmethyl- or a hexyl group,  
 alkylene is for example methylene, ethylene, propylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene or decamethylene,  
 C 3 -C 6 -alkenyl can be straight chain or branched and is preferably an allyl-, 2-butenyl-, 3-butenyl-, 2-methyl-2-propenyl-, 2-pentenyl-, 4-pentenyl-, 2-methyl-2-butenyl-, 3-methyl-2-butenyl-, 2-hexenyl-, 5-hexenyl-, 4-methyl-3-pentenyl- or 2,2-dimethyl-3-butenyl group,  
 alkenylene is for example ethenylene, propenylene, butenylene, pentenylene, hexenylene, hexathenylene, heptenylene, octenylene, nonenylene or decenylene,  
 C 3 -C 6 -alkinyl can be straight chain or branched and is preferably a propargyl-, 2-butinyl-, 3-butinyl-, 4-pentinyl-, 5-hexinyl- or 4-methyl-2-pentinyl group,  
 alkinylene is for example propinylene, butinylene, pentinylene, hexinylene, heptinylene, octinylene, noninylene or decinylene,  
 C 3 -C 8 -cycloalkyl is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl,  
 C 1 -C 6 -hydroxyalkyl contains a hydroxyl group in one of the above-named C 1 -C 6 -alkyl residues, especially in the form of the hydroxymethyl- and hydroxyethyl group, wherein  
 C 1 -C 6 -alkoxy, C 3 -C 6 -alkenyloxy, C 3 -C 6 -alkinyloxy each contain, aside from the oxygen atom, one of the C 1 -C 6 -alkyl-, C 3 -C 6 -alkenyl- and/or C 3 -C 6 -alkinyl groups named above and the methoxy-, ethoxy-, isopropoxy-, tert-butoxy-, allyloxy- and propargyloxy groups are preferred and is to be understood as among C 1 -C 6 -alkoxy entirely or partially substituted with fluorine, for example difluormethoxy, trifluormethoxy or 2,2,2-trifluorethoxy,  
 C 1 -C 6 -alkylthio, C 3 -C 6 -alkenylthio, C 3 -C 6 -alkinylthio each contain, aside from the sulfur atom, one of the C 1 -C 6 -alkyl-, C 3 -C 6 -alkenyl- or C 3 -C 6 -alkinyl groups named above, especially the methylthio-, ethylthio-, isopropylthio- and tert-butylthio groups,  
 C 3 -C 8 -cycloalkyloxy and C 3 -C 8 -cycloalkylthio are preferred as cyclopentyloxy- and cyclopentylthio- and/or cylohexyloxy- and cyclohexylthio groups,  
 C 1 -C 7 -alkanoyloxy groups contain, aside from the oxygen atom, an aliphatic acyl residue with 1 to 7 carbon atoms, especially the acetoxy-, propionyloxy- and pivaloyloxy groups,  
 C 2 -C 7 -alkoxycarbonyl groups contain, aside from the carbonyl group, one of the C 1 -C 6 -alkoxy groups mentioned above, especially the methoxycarbonyl-, ethoxycarbonyl-, isopropoxycarbonyl-, isobutoxycarbonyl-and tert-butoxycarbonyl group,  
 C 2 -C 7 -alkoxycarbonyloxy groups contain, aside from the oxygen atom, one of the C 2 -C 7 -alkoxycarbonyl residues mentioned above, especially the methoxycarbonyloxy-, ethoxycarbonyloxy-, isopropoxycarbonyloxy-, isobutoxycarbonyloxy-and tertbutoxycarbonyl group as well as the allyloxycarbonyloxy group,  
 C 2 -C 7 -alkylaminocarbonyl and C 3 -C 13 -dialkylaminocarbonyl groups contain, beside the carbonyl group, an alkylamino- and/or dialkylamino residue, whose C 1 -C 6 -alkyl groups have the above meanings, wherein the dimethylaminocarbonyl-, diethylaminocarbonyl- and the diisopropylaminocarbonyl groups are preferred, and  
 aside from the unsubstituted amino group, one of the following C 1 -C 6 -alkylamino groups and/or di-(C 1 -C 6 -alkyl)amino groups are to be understood under the amino groups of the formula NR 5 R 6 ,  
 C 1 -C 6 -alkylamino contains one of the C 1 -C 6 -alkyl groups mentioned above, especially in form of the methylamino-, ethylamino-, propylamino-, isopropylamino-, butylamino- and the tert-butylamino group,  
 di-(C 1 -C 6 -alkyl)amino carries two of the same or different of the above named C 1 -C 6 -alkyl groups on the nitrogen atom, especially in form of the dimethylamino-, diethylamino-, dipropylamino-, diisopropylamino-, isopropylmethylamino-, dibutylamino- or tert-butylmethylamino group,  
 C 1 -C 6 -acyl is the residue of an aliphatic saturated or unsaturated, straight chain, branched or cyclic carboxylic acid, especially in form of the formyl-, acetyl-, propionyl-acryloyl-, butyryl-, isobutyryl-, methacryloyl-, cyclopropylcarbonyl-, pentanoyl-, pivaloyl-, cyclobutylcarbonyl-, hexanoyl- and the dimethylacryloyl group,  
 C 1 -C 6 -alkansulfonyl is preferably the methanesulfonyl-, ethanesulfonyl-, propanesulfonyl-, butanesulfonyl-, pentanesulfonyl- and the hexanesulfonyl group, saturated rive- to seven-membered heterocycles with one or two hetero-atoms are especially tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, hexahydroazepinyl, piperazinyl, hexahydrodiazepinyl or morpholinyl,  
 monocyclic aromatic five- or six-membered heterocycles with one to three heteroatoms are especially furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl or triazinyl,  
 anellated bi and tricydic aromatic or partially hydrated carbocycic ring systems with 8 to 16 ring atoms and at least one aromatic ring are preferably benzocyclobutyl, indanyl, indenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, biphenylenyl, fluorenyl, anthryl, dihydroanthryl, phenanthryl, dihydrophenanthryl, dibenzocycloheptenyl, dihydrodibenzocycloheptenyl, dihydrodibenzocyclooctenyl or tetrahydrodibenzocyclooctenyl, wherein mono- or dioxo-derivates, wherein, the residues of indanone, tetralone, anthrone, anthraquinone, fluorenone, phenanthrone, dibenzocycloheptenone, dihydrodibenzocycloheptenone or tetrahydrodibenzocyclooctenone are, for example, also to be understood as partially hydrated carbocyclic ring systems,  
 anellated bi- and tricyclische aromatic or partially hydrated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring are, for example, imidazothiazolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, dihydrobenzothienyl, indolyl, indolinyl, benzimidazolyl, indazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzofurazanyl, benzothiadiazolyl, benzotriazolyl, oxazolopyridyl, thiazolopyridyl, isothiazolopyridyl, imidazopyridyl, pyrazolopyridyl, thienopyrimidinyl, chromanyl, benzopyranyl, quinolyl, isoquinolyl, dihydroquinolyl, tetrahydroquinolyl, benzodioxanyl, quinoxalinyl, quinazolinyl, naphthyridinyl, carbazolyl, tetrahydrocarbazolyl, pyridoindolyl, acridinyl, phenothiazinyl, dihydrodibenzoxepinyl, benzocycloheptathienyl, dihydrothienobenzothiepinyl, dihydrodibenzothiepinyl, octahydrodibenzothiepinyl, dihydrodibenzazepinyl, octahydrodibenzazepinyl, benzocycloheptapyridyl, dihydropyridobenzodiazepinyl, dihydrodibenzoxazepinyl, dihydropyridobenzoxepinyl, dihydropyridobenzoxazepinyl, dihydrodibenzothiazepinyl or dihydropyridobenzothiazepinyl, wherein their mono- or dioxo-derivates and/or optionally their possible tautomeres are also to be understood as partially hydrated heterocyclic ring systems, for example, the residues of indolinone, isatin, benzoxazolone and/or their tautomeres hydroxybenzoxazol, of benzisoxazolone, benzothiazolone, benzoisothiazolone and benzimidazolone and/or their tautomeres, hydroxybenzisoxazol, hydroxybenzothiazol, hydroxybenzoisothiazol and hydroxybenzimidazol, of indazolinone, of oxazolopyridinone, thiazolopyridinones, pyrazolopyridinones and imidazopyridinones and/or their tautomeres hydroxyoxazolopyridine, hydroxythiazolopyridines, hydroxypyrazolopyridines and hydroxyimidazopyridines, the residues of chromanone, chromone, quinolinone, dihydroquinolinone, tetrahydrocarbazolone, acridone, of dihydrodibenzoxepinones, benzocycloheptathiophenones, dihydrothienobenzothiepinones, dihydrodibenzothiepinones, dihydrodibenzoazepinones, benzocycloheptapyridinones, dihydropyridobenzoxazepinones, dihydrodibenzothiazepinones and of dihydropyridobenzothiazepinones,  
 saturated and unsaturated monocyclic, four- to eight-membered heterocycles are —NR 13 R 15  as a grouping which, aside from the essential nitrogen atom, can optionally contain one or two further hetero-atoms selected from N and/or S and/or O, for example azetidine, pyrrolidine, piperidine, (1H)tetrahydropyridine, hexabydroazepine, (1H)tetrahydroazepine, octahydroazocine, pyrazolidine, piperazine, hexahydrodiazepine, morpholine, hexahydrooxazepine, thiomorpholine or thiomorpholine-1,1-dioxide,  
 saturated or unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, represent —NR 13 R 15  as a grouping which, aside from the essential nitrogen atom optionally contain one or two further hetero-atoms, selected from N and/or S and/or O, for example 5-aza-bicyclo[2.1.1]hexane, 2-aza-bicyclo[2.2.1]heptane, 7-aza-bicyclo[2.2.1]heptane, 2,5-diaza-bicyclo[2.2.1]heptane, 2-aza-bicyclo[2.2.2]octane, 8-a-bicyclo[3.2.1]octane, 2,5-diaza-bicyclo[2.2.2]octane, 9-aza-bicyclo[3.3.1]nonane, indoline, isoindoline, (1H)dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)-tetrahydroquinoxaline, (4 Hz dihydrobenzoxazine, (4H)-dihydrobenothiazine, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[c]azepine, (1H)tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol, (10H)-dihydroacridine, 1,2,3,4-tetrahydroacridanone, (10H)-phenoxazine, (10H)-phenothiazine, (5H)-dibenzazepine, (5H)-dihydrodibenzazepine, (5H)-octahydrodibenzazepine, (5H)-dihydrodibenzodiazcpine, (11H) dihydrodibenzo[b,e]oxazepine, (11H)dihydrodibenzo[b,e]thiazepine, (10H)-dihydrodibenzo[b,f]oxazepine, (10H)-dihydrodibenzo[b,f]thiazepine or (5H)-tetrahydrodibenzazocine, as well as optionally possible  
 tautomeres in the case of substitution of the heterocycle as such or in an anellated ring system by free hydroxy-, mercapto- and/or amino groups, and their  
 stereoisomers such as, if applicable, cis/trans-isomers, endo/exo-isomers, optic isomers such as enantiomers, diastereomers as pure isomers or mixtures and/or racemic mixtures as well as the pharmacologically acceptable acid addition salts with inorganic or organic acids, wherein the hydrochlorides, hydrobromides, hydrolodides, sulfates and phosphates, are preferred as addition salts with suitable inorganic acids and acetates, benzoates, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, ascorbate, salicylate, formiate, glutarate, tricarballylate, citrates, fumarates, gluconates, malates, maleates, methanesulfonates, lactates, oxalates, succinates, tartrates and toluolsulfonates, for example p-toluolsulfonate are preferred as addition salts of organic acids.  
 
     
     
         4 . Use of compounds according to claims  1 - 3 , characterized in that the substitutents labelled in formula (I)  
       
         
           
           
               
               
           
         
       
       have the following meanings: 
 R 1  is hydrogen, halogen, cyano, C 1 -C 6 -alkyl, trifluoromethyl, C 3 -C 8 -cycloalkyl, C 1 -C 4 -hydroxyalkyl, hydroxy, C 1 -C 4 -alkoxy, benzyloxy, C 1 -C 4 -alkanoyloxy, C 1 -C 4 -alkylthio, C 2 -C 5 -alkoxycarbonyl, aimnocarbonyl, C 3 -C 9 -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy or NR 5 R 6 , wherein 
 R 5  and  
 R 6  are selected independently from each other form hydrogen and C 1 -C 6 -alkyl,  
 
 R 2  is hydrogen, halogen, C 1 -C 6 -alkyl, trifluoromethyl or hydroxy, wherein  
 R 1  and R 2 , in the case they are adjacent, optionally form a bridge which are selected from the group of bridge members —(CH 2 ) 4 — and —(CH═CH) 2 — and —CH 2 O—CR 7 R 8 —O—, wherein 
 R 7  and  
 R 8  can be, independently from each other, hydrogen and C 1 -C 6 -alkyl,  
 
 R 3  is selected from hydrogen, halogen and C 1 -C 6 -alkyl and  
 R 4  is selected from hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl, hydroxy, C 1 -C 6 -alkoxy and benyloxy,  
 k is 0 or 1,  
 A is C 1 -C 6 -alkylene, which is optionally substituted once to three-fold by C 1 -C 3 -alkyl, hydroxy, fluorine or phenyl, 
 1,2-cyclopropylene,  
 C 2 -C 6 -alkenylene, which is optionally substituted one to three-fold by C 1 -C 3 -alkyl, hydroxy, fluorine, cyano, or phenyl,  
 C 4 -C 6 -alkadienylene, which is optionally substituted once or twice by C 1 -C 3 -alkyl, fluorine, cyano, or phenyl,  
 1,3,5-hexatrienylene, which is optionally substituted by C 1 -C 3 -alkyl, fluorine, or cyano,  
 ethinylene or  
 C 2 -C 6 -alkylene, wherein a methylene unit can be isosterically replaced by O, S, NR 9 , CO, SO or SO 2 , and wherein the isosteric substitute, with the exception of ═CO, cannot be adjacent to the amide group, and wherein 
 R 9  is hydrogen, C 1 -C 3 -alkyl, C 1 -C 6 -acyl or methanesulfonyl,  
 
 
 D is selected from C 1 -C 10 -alkylene, which is optionally substituted once or twice by C 1 -C 3 -alkyl or hydroxy, 
 C 2 -C 10 -alkenylene, optionally substituted once or twice by C 1 -C 3 -alkyl or hydroxy, wherein the double bond can also be to ring E or  
 C 3 -C 10 -alkinylene, which is optionally substituted once or twice by C 1 -C 3 -alkyl or hydroxy, and can be selected as well from  
 C 1 -C 10 -alkylene, C 2 -C 10 -alkenylene or C 3 -C 10 -alkinylene, in which one to three methylene units are isosterically replaced by O, S, NR 10 , CO, SO or SO 2 , wherein  
 R 10  has the same meaning as R 9 , but is selected independently therefrom,  
 
 E is  
                     
  wherein the heterocyclic ring can optionally have a double bond and  
 n and p can be, independent of each other, 0, 1, 2 or 3, with the proviso that n+p≦4,  
 q is 2 or 3,  
 R 11  is selected from hydrogen, C 1 -C 3 -alkyl, hydroxy, hydroxymethyl, carboxy or C 2 -C 7 -alkoxycarbonyl and  
 R 12  is selected from hydrogen or an oxo group adjacent to the nitrogen atom,  
 G is selected from hydrogen, 
 G1, G2, G3, G4 and G5, wherein 
 G1 represents the residue  
 —(CH 2 ) r —(CR 14 R 15 ) s —R 13   (G1)  
  wherein 
 r is 0, 1 or 2 and  
 s is 0 or 1,  
 
 
 
 R 13  is selected from hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl, C 3 -C 6 -alkinyl, C 3 -C 8 -cycloalkyl, 
 benzyl, phenyl,  
 monocyclic aromatic five- or six-membered heterocycles, which contain one to three hetero-atoms from the group N and/or S and/or O and are either bound directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated carbocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, whereby the bond can occur either over an aromatic or a hydrated ring and either directly or over a methylcne group,  
 anellated bi- and tricyclic aromatic or partially hydrated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms can be selected from the groups N and/or S and/or O and the bond can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 
 R 14  has the same meaning as R 13 , but is selected independently thereof,  
 R 15  is selected from hydrogen, hydroxy, methyl, benzyl or phenyl, 
 monocyclic aromatic five- or six-membered heterocycles, which can contain one to three hetero-atoms selected from the group N and/or S and/or O and are bound either directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated carbocyclic ring systems with 8 to 16 ring atoms and at least einem aromatic ring, wherein the bond can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 anellated bi- and tricyclic aromatic or partially hydrated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms can be selected from the group N and/or S and/or O and the bond can occur either over an aromatic or a hydrated ring and either directly or over a methylene group,  
 
 G2 is selected from the residues  
                     
  wherein the substituents R 13  and R 15  the can have the above meaning, or the group  
 —NR 13 R 15    can also be a nitrogen heterocycle bound over the nitrogen atom, selected from    saturated or unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from the essential nitrogen atom, can optionally contain one or two further hetero-atoms selected from N and/or S and/or O, or    saturated or unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from the essential nitrogen atom, can optionally contain one or two further hetero-atoms selected from N and/or S and/or O,    
 G3 is the residue  
 —SO 2 —(CH 2 ) r  R 13   (G3),  
 G4 is the residue  
                     
  wherein 
 Ar 1  and  
 Ar 2  are selected independently of each other from phenyl, pyridyl or naphthyl,  
 
 G5 is the residue  
 —COR 16   (G5)  
  wherein  
 R 16  is trifluoromethyl, C 1 -C 6 -alkoxy, C 3 -C 6 -alkenyloxy or benzyloxy and 
 aromatic ring systems in which the substituents R 1 , R 2 , R 4 , R 13 , R 14 , R 15 , R 16 , Ar 1  and Ar 2  and/or in the ring system —NR 13 R 15  can carry independently of each other one to three of the same or different substituents from the series halogen, cyano, C 1 -C 6 -alkyl, trifluoromethyl, C 3 -C 8 -cycloalkyl, phenyl, benzyl, hydroxy, C 1 -C 6 -alkoxy, which is optionally entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C 1 -C 6 -alkylthio, carboxy, C 1 -C 6 -alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C 1 -C 6 -alkylamino, di-(C 1 -C 6 -alkyl)-amino, wherein two adjacent groups on the aromatic ring or ring system can form an additional ring over a methylenedioxy bridge.  
 
 
     
     
         5 . The use of compounds according to claims  14 , characterized in that the substiutents labelled in formula (I)  
       
         
           
           
               
               
           
         
       
       have the following meanings: 
 R 1  is hydrogen, halogen, cyano, methyl, trifluoromethyl, hydroxy, C 1 -C 4 -alkoxy, ethylthio, methoxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, carboxy, and phenoxy,  
 R 2  is hydrogen, halogen, trifluoromethyl or hydroxy,  
 R 3  is hydrogen or halogen,  
 R 4  is selected from hydrogen, C 1 -C 3 -alkyl, hydroxy and C 1 -C 3 -alkoxy,  
 k is 0 or 1,  
 A is C 2 -C 6 -alkylene, which is optionally substituted once or twice by C 1 -C 3 -alkyl, hydroxy or fluorine, as well as 
 C 2 -C 6 -alkenylene, which is optionally substituted once or twice by C 1 -C 3 -alkyl, hydroxy or fluorine,  
 C 4 -C 6 -alkadienylene, which is optionally substituted by is C 1 -C 3 -alkyl or by one or two fluorine atoms,  
 1,3,5-hexatrienylene, which is optionally substituted by fluorine, or  
 C 2 -C 6 -alkylene, wherein a methylene unit can be isosterically replaced by O, S, CO or SO 2 , and the isosteric substitute, with the exception of ═CO cannot be adjacent to the amide group and,  
 
 D is C 1 -C 8 -alkylene, which is optionally substituted once twice by methyl or hydroxy, 
 C 2 -C 8 -alkenylene, which is optionally substituted once or twice by methyl or hydroxy, wherein the double bond can also be to ring E,  
 C 3 -C 8 -alkinylene, which is optionally substituted once or twice by methyl or hydroxy, as well as  
 C 1 -C 8 -alkylene, C 2 -C 8 -alkenylene or C 3 -C 8 -alkinylene, in which one to three methylene units can be isosterically replaced by O, S, NH, N(CH 3 ), N(COCH 3 ), N(SO 2 CH 3 ), CO, SO or SO 2 ,  
                     
  wherein the heterocyclic ring can optionally have a double bond and  
 
 n and  
 p can be independent of each other 0, 1, 2 or 3, with the proviso that n+p≦3,  
 q is 2 or 3,  
 R 11  is selected from hydrogen, C 1 -C 3 -alkyl, hydroxy, hydroxymethyl and  
 R 12  is selected from hydrogen or an oxo group which is adjacent to the nitrogen atom,  
 G is hydrogen or 
 G1, G2, G3, G4 and G5, wherein 
 G1 represents the residue  
 —(CH 2 ) r —(CR 14 R 15 ) s —R 13   (G3)  
  wherein 
 r is 0, 1 or 2 and  
 s is 0 or 1,  
 
 
 
 R 13  is selected from hydrogen, C 1 -C 6 -alkyl, C 3 -C 8 -cycloalkyl, benzyl or phenyl, 
 benzocyclobutyl, indanyl, indenyl, oxoindanyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, oxotetrahydronaphthyl, biphenylenyl, fluorenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, phenanthryl, dihydrophenanthryl, oxodihydrophenanthryl, dibenzocycloheptenyl, oxodibenzocycloheptenyl, dihydrodibenzocycloheptenyl, oxodihydrodibenzocycloheptenyl, dihydrodibenzocyclooctenyl, tetrahydrodibenzocyclooctenyl and oxotetrahydrodibenzocyclooctenyl bound directly or over a methylene group,  
 furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, imidazothiazolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, dihydrobenzothienyl, indolyl, indolinyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolinyl, benzisoxazolyl, oxobenzisoxazolinyl, benzothiazolyl, oxobenzthiazolinyl, benzoisothiazolyl, oxobenzoisothiazolinyl, benzimidazolyl, oxobenzimidazolinyl, indazolyl, oxoindazolinyl, benzofurazanyl, benzothiadiazolyl, benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, isothiazolopyridyl, imidazopyridyl, oxodihydroimidazopyridyl, pyrazolopyridyl, oxodihydropyrazolopyridyl, thienopyrimidinyl, chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl, isoquinolyl, dihydroquinolyl, oxodihydroquinolinyl, tetrahydroquinolyl, oxotetrahydroquinolinyl, benzodioxanyl, quinoxalinyl, quinazolinyl, naphthyridinyl, carbazolyl, tetrahydrocarbazolyl, oxotetrahydrocarbazolyl, pyridoindolyl, acridinyl, oxodihydroacridinyl, phenothiazinyl, dihydrodibenzoxepinyl, oxodihydrodibenzoxepinyl, benzocycloheptathienyl, oxobenzocycloheptathienyl, dihydrothienobenzothiepinyl, oxodihydrothienobenzothiepinyl dihydrodibenzothiepinyl, oxodihydrodibenzothiepinyl, octahydrodibenzothiepinyl, dihydrodibenzazepinyl, oxodihydrodibenzazepinyl, octahydrodibenzazepinyl, benzocycloheptapyridyl, oxobenzocycloheptapyridyl, dihydropyridobenzodiazepinyl, dihydrodibenzoxazepinyl, dihydropyridobenzoxepinyl, dihydropyridobenzoxazepinyl, oxodihydropyridobenzoxazepinyl, dihydrodibenzothiazepinyl, oxodihydrodibenzothiazepinyl, dihydropyridobenzothiazepinyl, oxodihydropyridobenzothiazepinyl, bound directly or over a methylene group,  
 
 R 14  has the same meaning as R 13 , but is selected independently therefrom,  
 R 15  is selected from hydrogen, hydroxy, methyl, benzyl or phenyl, 
 indanyl, indenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, benzofuryl, benzothienyl, indolyl, indolinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, chromanyl, quinolyl or tetrahydroquinolyl bound directly or over a methylene group,  
 
 G2 is selected from the residues  
                     
  wherein the substituents R 13  and R 15  can have the above meanings, or represents the grouping  
 —NR 13 R 15    each over the nitrogen-bound ring atom of azetidine, pyrrolidine, piperidine, (1H)tetrahydropyridine, hexahydroazepine, (1H)tetrahydroazepine, octahydroazocine, pyrazolidine, piperazine, hexyhydrodiazepine, morpholine, hexahydrooxazepine, thiomorpholine, thiomorpholine-1,1-dioxide, 5-aza-bicyclo[2.1.1]hexane, 2-aza-bicyclo[2.2.1]heptane, 7-aza-bicyclo[2.2.1]heptane, 2,5-diaza-bicyclo[2.2.1]heptane, 2-aza-bicyclo[2.2.2]octane, 8-aza-bicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, 9-azabicyclo[3.3.1]nonane, indoline, isoindoline, (1H)-dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)-tetrahydroquinoxaline, (4H)-dihydrobenzoxazine,    
 (4H)-dihydrobenzothiazine, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[c]azepine, (1H)-tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydro-9H-pyrido[3,4b]indole, (10H)-dihydroacridine, 1,2,3,4-tetrahydroacridanone, (10H)-phenoxazine, (10H)-phenothiazine, (5H)-dibenzazepine, (5H)-dihydrodibenzazepine, (5H)-Octahydrodibenzazepine, (5H)-dihydrodibenzodiazepine, (11H)-dihydrodibenzo[b,e]oxazepine, (11H)-dihydrodibenzo[b,e]thiazepine, (10H)-dihydrodibenzo[b,f]oxazepine, (10H)-dihydrodibenzo[b,f]thiazepine or (5H)-tetrahydrodibenzazocine, 
 G3 is the residue  
 —SO 2 —(CH 2 ) r  R 13   (G3),  
 G4 is the residue  
                     
  wherein 
 Ar 1  and  
 Ar 2  are selected independently of each other from phenyl, pyridyl or naphthyl,  
 
 
 G5 is the residue  
 —COR 16   (G5)  
  wherein  
 R 16  is trifluoromethyl, C 1 -C 6 -alkoxy, C 3 -C 6 -alkenyloxy or benzyloxy and 
 aromatic ring systems in which the substituents can be substituted independently of each other by one to three of the same or different substituents from the series halogen, cyano, C 1 -C 6 -alkyl, trifluoromethyl, C 3 -C 8 -Cycloalkyl, phenyl, benzyl, hydroxy, C 1 -C 6 -alkoxy, C 1 -C 6 -alkoxy, which can be entirely or partially substituted by fluorine, can carry benzyloxy, phenoxy, mercapto, C 1 -C 6 -alkylthio, carboxy, C 1 -C 6 -alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C 1 -C 6 -alkylamino, di-(C 1 -C 6 -alkyl)-amino, wherein two adjacent groups in the ring or ring system can form an additional ring over a methylenedioxy bridge.  
 
 
     
     
         6 . The use of compounds according to claims  1 - 5 , characterized in that the substituents labelled in formula (I)  
       
         
           
           
               
               
           
         
       
       have the following meaning: 
 R 1  is hydrogen, halogen, cyano, methyl, trifluoromethyl, hydroxy, methoxy or methoxycarbonyl,  
 R 2  is hydrogen or halogen,  
 R 3  is hydrogen,  
 R 4  is selected from hydrogen, C 1 -C 3 -alkyl or hydroxy,  
 k is 0 or 1,  
 A is selected from C 2 -C 6 -alkylene, which is optionally substituted once or twice by hydroxy or fluorine, or 
 C 2 -C 6 -alkenylene, which is optionally substituted once or twice by hydroxy or fluorine,  
 C 4 -C 6 -alkadienylene, which is optionally substituted by one or two fluorine atoms, 1,3,5-hexatrienylene or  
 C 2 -C 6 -alkylene, wherein a methylene unit can be isosterically replaced by O, S or CO, and the isosteric substitute, with the exception of ═CO, cannot be adjacent to the amide group and,  
 
 D is C 2 -C 8 -alkylene, which is optionally substituted by methyl or hydroxy 
 C 2 -C 8 -alkenylene, which is optionally substituted by methyl or hydroxy, wherein the double bond can also be to ring E, or  
 C 2 -C 8 -alkylene, C 2 -C 8 -alkenylene, wherein one to three methylene units can be isosterically replaced by O, NH, N(CH 3 ), N(COCH 3 ), N(SO 2 CH 3 ) or CO,  
 
 E is selected from the residues  
                     
  wherein the heterocyclic ring can optionally have a double bond and  
 n and p can be, independent of each other, 0, 1, 2 or 3, with the proviso that n+p≦3 and  
 q is 2  
 R 11  is hydrogen, methyl or hydroxyl and  
 R 12  is hydrogen or an oxo group adjacent to the nitrogen atom,  
 G is selected from hydrogen, C 3 -C 8 -cycloalkyl, methoxycarbonyl, tertbutoxycarbonyl, benzyloxycarbonyl, trifluoracetyl, diphenylphosphinoyl or the residues  
                     
  wherein  
 r is 0, 1 or 2 and  
 s is 0 or 1,  
 R 13  is hydrogen, methyl, benzyl or phenyl, 
 indanyl, indenyl, oxoindanyl, naphthyl, dihydronaphthyl, tetrahydronaphtbyl, oxotetrahydronaphthyl, fluorineenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, dibenzocycloheptenyl, oxodibenzocycloheptenyl, dihydrodibenzocycloheptenyl, oxodihydrodibenzocycloheptenyl bound directly or over a methylene group,  
 furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, imidazothiazolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, dihydrobenzothienyl, indolyl, indolinyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolinyl, benzisoxazolyl, oxobenzisoxazolinyl, benzothiazolyl, oxobenzthiazolinyl, benzoisothiazolyl, oxobenzoisothiazolinyl, benzimidazolyl, oxobenzimidazolinyl, benzofurazanyl, benzothiadiazolyl, benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, isothiazolopyridyl, imidazopyridyl, oxodihydroimidazopyridyl, pyrazolopyridyl, thienopyrimidinyl, chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl, isoquinolyl, dihydroquinolyl, oxodihydroquinolinyl, tetrahydroquinolyl, oxotetrahydroquinolinyl, benzodioxanyl, quinoxalinyl, quinazolinyl, naphthyridinyl, carbazolyl, tetrahydrocarbazolyl, oxotetrahydrocarbazolyl, pyridoindolyl, acridinyl, oxodihydroacridinyl, phenothiazinyl, dihydrodibenzoxepinyl, benzocycloheptathienyl, oxobenzocycloheptathienyl, dihydrothienobenzothiepinyl, oxodihydrothienobenzothiepinyl dihydrodibenzothiepinyl, oxodihydrodibenzothiepinyl, dihydrodibenzazepinyl, oxodihydrodibenzazepinyl, octahydrodibenzazepinyl, benzocycloheptapyridyl, oxobenzocycloheptapyridyl, dihydropyridobenzoxepinyl, dihydrodibenzothiazepinyl, oxodihydrodibenzothiazepinyl bound directly or over a methylene group,  
 
 R 14  is hydrogen, methyl, benzyl or phenyl,  
 R 15  is selected from hydrogen, hydroxy, methyl, benzyl, phenyl, 
 naphthyl, furyl, thienyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, benzofuryl, benzothienyl, indolyl, indolinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, chromanyl, quinolyl or tetrahydroquinolyl, bound directly or over a methylene group, wherein in formula (I)  
                     
 the group NR 13 R 15  can be selected from pyrrolidine, piperidine, (1H)tetrahydropyridine, hexahydroazepine, Octahydroazocine, piperazine, hexahydrodiazepine, morpholine, hexahydrooxazepine, 2-azabicyclo[2.2.1]heptane, 7-azabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.1]heptane, 8-azabicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, indoline, isoindoline, (1H)-dihydroquinoline, (1H)tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)-tetrahydroquinoxaline, (4H)-dihydrobenzoxazine, (4H)-dihydrobenzothiazine, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[d]azepine, (SH)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol, (10H)-dihydroacridine, 1,2,3,4-tetrahydroacridanone, (5H)-dihydrodibenzazepine, (5H)-dihydrodibenzodiazepine, (11H)-dihydrodibenzo[b,e]oxazepine, (11H)-dihydrodibenzo[b,e]thiazepine, (10H)-dihydrodibenzo[b,f]oxaze-pine or (5H)-tetrahydrodibenzazocine.  
 
 
     
     
         7 . The use of compounds according to claims  1 - 6 , characterized in that the substituents in labelled the formula (I)  
       
         
           
           
               
               
           
         
       
       have the following meanings: 
 R 1  is hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl or hydroxy,  
 R 2  and  
 R 3  are hydrogen,  
 R 4  is hydrogen or hydroxy,  
 k is 0 or 1,  
 A is selected from C 2 -C 6 -alkylene, which is optionally substitued once or twice by hydroxy or fluorine or, 
 C 2 -C 4 -alkylene, which is optionally substituted by fluorine,  
 C 4 -alkadienylene, which is optionally substituted by fluorine,  
 
 D is selected from C 2 -C 6 -alkylene, C 2 -C 6 -alkenylene, wherein the double bond can also be to ring E, and C 2 -C 6 -alkylene and C 2 -C 6 -alkenylene, wherein a methylene unit can be isosterically replaced by O, NH, N(CH 3 ) or CO or an ethylene group can be isosterically replaced by NH—CO and/or CO—NH or a propylene group can be isosterically replaced by NH—CO—O and/or O—CO—NH,  
 E is selected from pyrrolidine, piperidine, 1,2,5,6-tetrahydropyridine, hexahydroazepine, morpholine and hexahydro-1,4-oxazepine, wherein the heterocyclic ring optionally adjacent to the nitrogen atom, can be substituted by an oxo group,  
 G is selected from hydrogen, tert-butoxycarbonyl, diphenylphosphinoyl, or one of the residues  
                     
  wherein  
 r is 0 or 1 and  
 s is 0 or 1,  
 R 13  is hydrogen, methyl, benzyl or phenyl, 
 indenyl, oxoindanyl, naphthyl, tetrahydronaphthyl, fluorenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, dibenzocycloheptenyl, dihydrodibenzocycloheptenyl bound directly or over a methylene group,  
 furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, imidazothiazolyl, benzofuryl, benzothienyl, indolyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolinyl, benzothiazolyl, oxobenzthiazolinyl, benzimidazolyl, oxobenzimidazolinyl, benzofurazanyl, benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl, isoquinolyl, oxodihydroquinolinyl, tetrahydroquinolyl, oxotetrahydroquinolinyl, benzodioxanyl, quinazolinyl, acridinyl, oxodihydroacridinyl, phenothiazinyl, dihydrodibenzoxepinyl, benzocycloheptathienyl, dihydrothienobenzothiepinyl, dihydrodibenzothiepinyl, oxodihydrodibenzothiepinyl, dihydrodibenzazepinyl, oxodihydrodibenzazepinyl, octahydrodibenzazepinyl, benzocycloheptapyridyl, oxobenzocycloheptapyridyl, dihydrodibenzothiazepinyl bound directly or over a methylene group,  
 
 R 14  is hydrogen, methyl, benzyl or phenyl,  
 R 15  is hydrogen, hydroxy, methyl, benzyl or phenyl, 
 naphthyl, furyl, thienyl, pyridyl, benzofuryl, benzothienyl, indolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, chromanyl, quinolyl or tetrahydroquinolyl bound directly or over a methylene group, wherein in the formula  
                     
 the group NR 13 R 15  can be selected from pyrrolidine, piperidine, hexahydroazepine, morpholine, 2,5-diazabicyclo[2.2.1]heptane, indoline, isoindoline, (1H)-dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydroacridanone, (5H)-dihydrodibenzazepine, (11H)-dihydrodibenzo[b,e]-oxazepine or (11H)-dihydrodibenzo[b,e]thiazepine and  
 wherein aromatic ring systems in the substituents can be substituted, independently of each other, by one to three of the same or different substituents from the series halogen, cyano, C 1 -C 6 ′-alkyl, trifluoromethyl, C 3 -C 8 -cycloalkyl, phenyl, benzyl, hydroxy, C 1 -C 6 -alkoxy, C 1 -C 6 -alkoxy, which can be entirely or partially substituted by fluorine, can carry benzyloxy, phenoxy, mercapto, C 1 -C 6 -alkylthio, carboxy, C 1 -C 6 -alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C 1 -C 6 -alkylamino or di-(C 1 -C 6 -alkyl)-amino, whereby two adjacent groups on the aromatic ring or ring system for an additional ring over a methylenedioxy bridge.  
 
 
     
     
         8 . The use of compounds according to claims  1 - 7 , characterized in that the substituents labelled in the formula (I)  
       
         
           
           
               
               
           
         
       
       have the following meanings: 
 R 1  is hydrogen, fluorine, methyl, trifluoromethyl or hydroxy,  
 R 2  and  
 R 3  are hydrogen,  
 R 4  is hydrogen or hydroxy,  
 k is 0,  
 A is ethylene, propylene or butylene which can be each optionally substituted by hydroxy or once or twice by fluorine, or 
 ethenylene and/or vinylene or  
 1,3-butadienylene  
 
 D is selected from C 2 -C 6 -alkylene or C 2 -C 6 -alkenylene, wherein the double bond can also be to ring E,  
 E is selected from pyrrolidine, piperidine, hexahydroazepine or morpholine,  
 G is selected from benzyl, phenethyl, fluorenylmethyl, anthrylmethyl, diphenylmethyl, fluorenyl or dihydrodibenzocycloheptenyl, furylmethyl, thienylmethyl, thiazotylmethyl, pyridylmethyl, benzothienylmethyl, quinolylmethyl, phenyl-thienylmethyl, phenyl-pyridylmethyl, dihydrodibenzoxepinyl, dihydrodibenzothiepinyl, 
 acetyl, pivaloyl, phenylacetyl, diphenylacetyl, diphenylpropionyl, naphthyl acetyl, benzoyl, naphthoyl, anthrylcarbonyl, oxofluorenylcarbonyl, oxodihydroanthrylcarbonyl or dioxodihydroanthrylcarbonyl,  
 furoyl, pyridylcarbonyl, chromonylcarbonyl, quinolylcarbonyl,  
 naphthylaminocarbonyl, dibenzylaminocarbonyl, benzylphenylaminocarbonyl, diphenylaminocarbonyl, indolinyl-1-carbenyl, dihydrodibenzazepin-N-carbonyl, tetrahydroquinolinyl-N-carbonyl, tetrahydrobenzo[b]azepinyl-N-carbonyl,  
 
 methanesulfonyl, phenylsulfonyl, p-toluolsulfonyl, naphthylsulfonyl, quinolinsulfonyl and  
 diphenylphosphinoyl,  
 wherein aromatic ring systems can be substituted independently of each other by one to three of the same or different substituents from the series halogen, cyano, C 1 -C 6 -alkyl, trifluoromethyl, C 3 -C 8 -cycloalkyl, phenyl, benzyl, hydroxy, C 1 -C 6 -alkoxy, C 1 -C 6 -alkoxy, which can be entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C 1 -C 6 -alkylthio, carboxy, C 1 -C 6 -alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C 1 -C 6 -alkylamino or di-(C 1 -C 6 -alkyl)-amino, wherein two adjacent groups in the ring or ring system can form an additional ring over a methylendioxy bridge.  
 
     
     
         9 . Use according to one of the claims  1 - 8 , characterized in that one or more of the following compounds and/or pharmaceutically acceptable acid addition salts thereof are used for the production of the medicament 
 N-[2-(1-benzylpiperidin-4-yl)-ethyl]-3-(pyridin-3-yl)-propionamide,    N-{2-[1-(2-phenylethyl)-piperidin-4-yl]-ethyl}-3-(pyridin-3-yl)-propionamide,    N-{2-[1-(4-phenylbutyl)-piperidin-4-yl]-ethyl}-3-(pyridin-3-yl)-propionamide,    N-{2-[1-(4-hydroxy-4-phenylbutyl)-piperidin-4-yl]-ethyl}-3-(pyridin-3-yl)-propionamide,    N-[2-(1-diphenylmethylpiperidin-4-yl)-ethyl]-3-(pyridin-3-yl)-propionamide,    N-[3-(1-diphenylmethylpiperidin-4-yl)-propyl]-3-(pyridin-3-yl)-propionamide, or    N-[4-(1-diphenylmethylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)-propionamide.    
     
     
         10 . Use according to any one of the claims  1 - 8 , characterized in that one or more of the following compounds and/or pharmacologically acceptable acid addition salts thereof are used for the production of a medicament 
 N-[4(1-benzylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,    N-{4-[1-(2-phenylethyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide,    N-{4-[1-(4-biphenylylmethyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide,    N-{4-[1-(1-naphthylmethyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide,    N-{4-[1-(9-anthrymethyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide,    N-{4-[1-(Cyclohexylphenylmethyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide, or    N-{4-[1-(10,11-dihydro-5H-dienzo[a,d]cycloheptene-5-yl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide.    
     
     
         11 . Use according to any one of the claims  1 - 8 , characterized in that one or more of the following compounds and/or pharmacologically acceptable acid addition salts thereof are used for the production of a medicament 
 N-[2-(1-diphenylmethylpiperidin-4-yl)-ethyl]-3-(pyridin-3-yl)-acrylamide,    N-[3-(1-diphenylmethylpiperidin-4-yl)-propyl]-3-(pyridin-3-yl)-acrylamide,    N-[5-(1-diphenylmethylpiperidin-4-yl)-pentyl]-3-(pyridin-3-yl)-acrylamide,    N-[6-(1-diphenylmethylpiperidin-4-yl)-hexyl]-3-(pyridin-3-yl)-acrylamide, or    N-[4-(1-diphenylmethylpiperidin-4-yl)-butyl]-5-(pyridin-3-yl)-2,4-pentadiene acid amide.    
     
     
         12 . Use according to any one of the claims  1 - 8 , characterized in that one or more of the following compounds and/or pharmacologically acceptable acid addition salts thereof are used for the production of a medicament 
 N-(4-{1-[bis-(4-fluorophenyl)-methyl]-piperidin-4-yl)-butyl}-3-(pyridin-3-yl)-acrylamide,    N-(4-{1-[bis-(2-chlorophenyl)-methyl]-piperidin-4-yl}-butyl)-3-(pyridin-3-yl)-acrylamide,    N-[4-(1-diphenylmethylpiperidin-4-yl)-butyl]-3-(2-fluoropyridin-3-yl)-acrylamide, or    N-[4-(1-diphenylmethylpiperidin-4-yl)-butyl]-3-(6-fluoropyridin-3-yl)-acrylamide.    
     
     
         13 . Use according to any one of the claims  1 - 8 , characterized in that one or more of the following compounds are used for the production of a medicament 
 N-[4-(1-diphenylmethylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,    N-[4-(1-diphenylmethylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide dihydrochloride or,    N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)-acrylamide methanesulfonate.    
     
     
         14 . Use according to any one of the claims  1 - 13  characterized in that the compounds according to the general formula (I) are combined with one or more other active ingredients for the respective indications such as cytostatic agents or immunosuppressive agents.  
     
     
         15 . Medicament for cytostatic or immunomodulatory and/or immunosuppressive treatment in human or veterinary medicine, characterized in that it comprises a compound according to formula (I) corresponding to the substituent definitions given in claims  1 - 13  in combination with a cytostatic agent or an immunosuppressive agent, optionally together with further active ingredients suitable in the named indications and suitable carriers, adjuvents and additives.  
     
     
         16 . Medicament according to  claim 15  for cytostatic treatment, characterized in that together with a compound according to formula (I) and aside from pharmaceutically acceptable carriers and adjuvents, it comprises in combination one or more cytostatic agents from the series of anti-metabolites such as, cytarabine, 5-fluoruracil, 6-mercaptopurine or methotrexate, alkylating agents such as busulfan, carmustine, cisplatin, carboplatin, cyclophosphamide, dacarbazine, melphalan or thiotepa, DNA-intercalating substances and topoisomerase inhibitors such as actinomycin D, daunorubicin, doxorubicin, mitomycin C, mitoxantrone, etoposide, topotecan or irinotecan, spindle poisons such as vincristine, navelbin, taxol, or taxoter, hormonally active agents such as tamoxifen, flutiamide, formestan or goserelin or from the series of other cytostatic agents with complex modes of action such as L-asparaginase, bleomycin or hydroxyurea or from the group of the modulators of P-glycoprotein, MRP, glutathione-S-transferase, metallothionein, optionally together with futher medicines effective in these indications.  
     
     
         17 . Medicament according to  claim 15  for immunosuppressive treatment, characterized in that, together with a compounds according to formula (I) and aside from pharmaceutically acceptable carriers and adjuvents, it optionally comprises in combination one or more immunosuppressive agents from the series of the cyclosporins, such as cyclosporin A, tacrolimus, raparnycin, the group of antimetabolites such as methotrexate and azathioprine and the group of glucocorticoids, optionally together with further medicines effective in these indications.  
     
     
         18 . Use according to one of the claims  1 - 14 , characterized in that the production of the medicament serves for the treatment of tumors in connection with the indications gynacological tumors, ovarian carcinomas, testicle tumors, prostate carcinomas, skin cancer, kidney cancer, bladder tumors, esophagus carcinomas, stomach cancer, rectal carcinomas, pancreas carcinomas, thyroid cancer, adrenal tumors, various types of leukemia and lymphomas, Hodgkin's disease, tumor illnesses of the CNS, soft-tissue sarcomas, bone sarcomas, benign and malignant mesotheliomas, especially intestine cancer, liver cancer, breast cancer, bronchial and lung carcinomas, melanomas, acute and chronic leukemias and benign papillomatosis tumors.  
     
     
         19 . N-(4-diphenylmethyl-morpholin-2-ylmethyl)-3- (pyridin-3-yl)-acrylamide